目的 评价参麦注射液对中晚期肺癌化疗患者生活质量的影响。方法 64例中晚期非小细胞肺癌患者，随机分为治疗组（32例）和对照组（32例）。对照组采用NP化疗方案：第l、8天iv诺维本30 mg/m2；第l天静脉滴注顺铂80～100 mg/m2，配合水化；1个疗程3周。治疗组化疗方案同对照组，同时患者于化疗前3 d开始静脉滴注参麦注射液，50～100 mL/次，1 次/d，连用14 d。两组患者共治疗2个疗程。于第1个疗程第1天和第2个疗程结束后15 d评价患者生活质量。结果 治疗后两组患者躯体功能、角色功能、认知功能、情绪功能、社会功能5个维度及整体生活质量评分均较治疗前明显上升（P＜0.05），治疗组躯体、角色、情绪功能和整体生活质量评分均高于对照组（P＜0.05）；化疗后两组疲乏、疼痛、恶心呕吐评分均明显上升（P＜0.01，P＜0.05），治疗组评分均低于对照组（P＜0.01）；治疗组呼吸困难、失眠、食欲丧失、便秘评分低于对照组（P＜0.05）。结论 参麦注射液联合化疗能改善中晚期肺癌患者的生存质量。

Objective To evaluate Shenmai Injection on life quality of the patients suffered from moderate and advanced stages non-small cell lung cancer treated by chemotherapy. Methods The patients (64 cases) diagnosed as moderate and advanced non-small cell carcinoma were randomly divided into treatment (32 cases) and control (32 cases) groups. The patients in the control group were adopted NP regimen: the patients were iv injected with Navelbine (NVB, 30 mg/m2) on the days 1 and 8, and iv dripped with Cis-platinum (DDP, 80—100 mg/m2) on the day 1. A course lasted for three weeks. The chemotherapy regimen of the treatment group was the same as the control group. Meanwhile, the patients in the treatment group were iv injected with Shenmai Injection (50—100 mL) 3 d before chemotherapy, once daily for 14 d. Two groups were treated for two courses. The life quality was evaluated on the day 1 of the first course and the day 5 after the second course. Results After the treatment, the five dimensions of the two groups in body, role, cognitive, emotional, and social functions, and overall quality of life score were significantly more increased than those before the treatment (P < 0.05), and body, role, and emotional functions of the patients in the treatment group were higher than those in the control group with significant difference (P < 0.05). After chemotherapy, the fatigue, pain, nausea and vomiting scores of the two groups were significantly increased (P < 0.01, 0.05), and scores in the treatment group were lower than those in the control group with significant difference (P < 0.01). In the treatment group, the dyspnea, insomnia, loss of appetite, and constipation scores were lower than those in the control group (P < 0.05). Conclusion Shenmai Injection could improve the life quality of the patients suffered from moderate and advanced stages non-small cell lung cancer treated by chemotherapy.